No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Subcutaneous Tissue
|
Positive |
Positive |
(FIBROMA)
|
Neoplastic Lesions
|
Yes
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Positive |
Positive |
(POLYP, SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Vascular System (Unspecified)
|
Positive |
Positive |
(HEMANGIOSARCOMA)
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 6/50 7/51 10/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/52 2/51 10/54 11/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/49 0/47 1/52 2/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/50 0/50 2/48 1/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 20/49 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/50 6/49 12/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 21/50 36/49 29/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50
|
Neoplastic Lesions
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 1/59 0/60 4/60
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 0/60 0/59 3/60
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Clitoral Gland
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland C-Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA, ADENOMA
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
(POLYP)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Positive |
Positive |
(PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/60 2/44 3/75 1/60
|
May Have Been Related
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/60 2/45 14/75 20/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 2/60 1/45 7/75 6/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60
|
Neoplastic Lesions
|
Yes
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60
|
Neoplastic Lesions
|
No
|
TR-128
|
91-93-0 |
3,3'-Dimethoxybenzidine-4,4'-diisocyanate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-128
|
91-93-0 |
3,3'-Dimethoxybenzidine-4,4'-diisocyanate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-128
|
91-93-0 |
3,3'-Dimethoxybenzidine-4,4'-diisocyanate |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-128
|
91-93-0 |
3,3'-Dimethoxybenzidine-4,4'-diisocyanate |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-128
|
91-93-0 |
3,3'-Dimethoxybenzidine-4,4'-diisocyanate |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Positive |
Positive |
(BASAL CELL ADENOMA, SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-128
|
91-93-0 |
3,3'-Dimethoxybenzidine-4,4'-diisocyanate |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
(POLYP)
|
Neoplastic Lesions
|
No
|
TR-128
|
91-93-0 |
3,3'-Dimethoxybenzidine-4,4'-diisocyanate |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-128
|
91-93-0 |
3,3'-Dimethoxybenzidine-4,4'-diisocyanate |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Positive |
Positive |
ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 8/48 23/47 17/50 21/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 2/50 0/49 COMBINED 8/48 23/47 18/50 21/49
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Brain
|
Some Evidence |
Equivocal Evidence |
GRANULAR CELL TUMOR 0/49 3/50 1/50 1/50; GLIOMA 0/49 1/50 0/50 0/50, ASTROCYTOMA 0/49 1/50 0/50 0/50, OR OLIGODENDROGLIOMA 0/49 1/50 0/50 0/50 COMBINED 0/49 3/50 0/50 0/50
|
May Have Been Related
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Female |
Inhalation |
Brain
|
Equivocal Evidence |
Equivocal Evidence |
GLIOMA 0/50 1/50 1/48 3/50
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Some Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/48 0/49 1/48 1/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/48 0/49 3/48 0/48 COMBINED 0/48 0/49 4/48 1/48
|
May Have Been Related
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 6/50 8/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 0/50 5/50 6/50 COMBINED 7/50 6/50 12/50 15/50
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 0/47 3/49
|
Neoplastic Lesions
|
Yes
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Mice |
B6C3F1 |
Female |
Inhalation |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 1/47 6/48, ADENOCARCINOMA 0/50 2/50 3/47 19/48, OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/47 3/48 COMBINED 0/50 4/50 5/47 27/48
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/50 1/35 1/65 2/50
|
May Have Been Related
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50
|
May Have Been Related
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/35 3/65 1/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 6/65 8/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/35 1/65 3/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 0/65 2/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50
|
Neoplastic Lesions
|
Yes
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50
|
Neoplastic Lesions
|
No
|
TR-346
|
75-00-3 |
Chloroethane |
Mice |
B6C3F1 |
Male |
Inhalation |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-346
|
75-00-3 |
Chloroethane |
Rats |
F344/N |
Female |
Inhalation |
Brain
|
Equivocal Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-346
|
75-00-3 |
Chloroethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 1/48 OR CARCINOMA 3/49 7/48 COMBINED 3/49 8/48
|
May Have Been Related
|
No
|
TR-346
|
75-00-3 |
Chloroethane |
Rats |
F344/N |
Male |
Inhalation |
Skin
|
Equivocal Evidence |
Equivocal Evidence |
TRICHOEPITHELIOMA 0/49 1/46, SEBACEOUS GLAND ADENOMA 0/49 1/46, OR BASAL CELL CARCINOMA 0/49 3/46 COMBINED 0/49 5/46
|
Neoplastic Lesions
|
Yes
|
TR-346
|
75-00-3 |
Chloroethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ENDOMETRIAL CARCINOMA 0/49 43/50
|
Neoplastic Lesions
|
No
|
TR-083
|
1596-84-5 |
Daminozide |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-083
|
1596-84-5 |
Daminozide |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-083
|
1596-84-5 |
Daminozide |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-083
|
1596-84-5 |
Daminozide |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
(ADENOCARCINOMA, LEIOMYOSARCOMA)
|
Neoplastic Lesions
|
No
|
TR-510
|
64-17-5 |
Ethanol |
Mice |
MV |
Female |
Dosed-Water |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-510
|
64-17-5 |
Ethanol |
Mice |
MV |
Male |
Dosed-Water |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
CYSTADENOMA 1/46 6/46 8/47
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
CYSTADENOMA 1/43 9/44 8/42
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 9/49 6/48 22/49
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/49 4/48 17/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 1/48 7/49
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 11/50 11/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 10/50 16/50
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/49 6/48 4/49; ADENOSQUAMOUS CARCINOMA 0/49 2/48 2/49
|
Neoplastic Lesions
|
Yes
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/49 1/47 5/49
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Epididymis
|
Clear Evidence |
Equivocal Evidence |
SARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Equivocal Evidence |
FIBROSARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 13/50 14/50 20/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 3/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50
|
May Have Been Related
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 3/50 6/50
|
Neoplastic Lesions
|
No
|
TR-078
|
21416-87-5 |
ICRF-159 |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-078
|
21416-87-5 |
ICRF-159 |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-078
|
21416-87-5 |
ICRF-159 |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
Yes
|
TR-078
|
21416-87-5 |
ICRF-159 |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Uterus/Cervix
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-032
|
3778-73-2 |
Isophosphamide |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-032
|
3778-73-2 |
Isophosphamide |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-032
|
3778-73-2 |
Isophosphamide |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
No
|
TR-032
|
3778-73-2 |
Isophosphamide |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Mammary Gland
|
Positive |
Positive |
(FIBROADENOMA)
|
Neoplastic Lesions
|
Yes
|
TR-032
|
3778-73-2 |
Isophosphamide |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Uterus/Cervix
|
Positive |
Positive |
(LEIOMYOSARCOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Uterus/Cervix
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
CHOLANGIOCARCINOMA 0/53 0/53 1/52 9/52 30/51 HEPATOCHOLANGIOMA 0/53 0/53 0/52 2/52 6/51 ADENOMA 0/53 0/53 3/52 5/52 27/51
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/52 1/53 11/52
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA (GINGIVAL) 0/53 0/53 2/53 5/53 9/53
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 1/53 1/52 3/52 1/50 ADENOMA OR CARCINOMA 0/53 1/53 1/52 4 /52 2/50
|
Neoplastic Lesions
|
Yes
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 1/53 1/53 1/53 4/53 0/53
|
May Have Been Related
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/53 0/53 1/53 0/52 2/53 4/53 1/50 OR CHOLANGIOCARCINOMA 0/53 0/53 0/53 1/52 1/53 2/53 0/50
|
Neoplastic Lesions
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Some Evidence |
Equivocal Evidence |
CYSTIC KERATINIZING EPITHELIOMA (MULTIPLE) 0/53 0/53 0/53 0/53 0/53 1/52 0/50
|
May Have Been Related
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Some Evidence |
Some Evidence |
(ORAL MUCOSA) GINGIVAL SQUAMOUS CELL CARCINOMA 1/53 2/53 1/53 0/53 1/53 3/53 3/50
|
Neoplastic Lesions
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/53 0/53 0/53 0/52 2/52 0/52 2/49
|
May Have Been Related
|
Yes
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 1/53 1/53 0/53 1/53 5/53 2/53 1/50
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Equivocal Evidence |
HEPATOCHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 2/53 0/50 OR CHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 0/53 1/50
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 0/54 0/53 0/53 1/53 13/53 2/50 OR CHOLANGIOCARCINOMA 0/53 0/54 0/53 1/53 4/53 25/53 2/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/54 0/53 0/52 0/53 9/52 0/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
GINGIVAL SQAMOUS CELL CARCINOMA (ORAL MUCOSA) 1/53 2/54 1/53 0/53 4/53 10/53 5/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/51 0/54 0/52 0/53 0/52 3/51 1/49
|
May Have Been Related
|
Yes
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/53 0/54 0/53 0/53 5/53 0/53 2/50
|
Neoplastic Lesions
|
No
|
TR-081
|
512-56-1 |
Trimethylphosphate |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-081
|
512-56-1 |
Trimethylphosphate |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-081
|
512-56-1 |
Trimethylphosphate |
Rats |
F344/N |
Male |
Gavage |
Subcutaneous Tissue
|
Positive |
Positive |
(FIBROMA)
|
Neoplastic Lesions
|
Yes
|
TR-081
|
512-56-1 |
Trimethylphosphate |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/46 2/47 3/44 5/45
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/48 1/47 5/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/47 1/47 7/47 ADENOMA 5/48 10/47 19/47 18/47 ADENOMA OR CARCINOMA 5/48 11/47 20/47 19/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 1/46 2/47 5/46 13/44 ADENOMA 7/46 13/47 17/46 17/44 ADENOMA OR CARCINOMA 12/46 18/47 24/46 23/44
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 6/48 17/48 29/47 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 4/48 13/48 19/47 COMBINED 6/48 8/48 28/48 39/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 17/48 22/47 34/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 1/48 9/47 9/48 COMBINED 5/48 18/48 29/47 37/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN GRANULOSA CELL TUMOR 0/48 0/46 2/46 3/39 MALIGNANT GRANULOSA CELL TUMOR 0/48 0/46 0/46 3/39 COMBINED 0/48 0/46 2/46 5/39
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/48 0/46 2/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48)
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/45 1/47 4/46
|
Neoplastic Lesions
|
Yes
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/47 0/48 2/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/48 0/47 0/48 6/48 ADENOMA 3/48 6/47 16/48 16/48 ADENOMA OR CARCINOMA 3/48 7/47 16/48 17/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 1/47 2/47 0/47 7/46 ADENOMA 6/47 5/47 15/47 23/46 ADENOMA OR CARCINOMA 7/47 5/47 16/47 23/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 2/48 2/46 4/48 13/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 3/47 4/48 3/46 11/48 ADENOMA 12/47 15/48 16/46 24/48 ADENOMA OR CARCINOMA 16/47 19/48 17/46 24/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 5/47 10/47 16/48 28/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 0/47 2/47 6/48 23/48 COMBINED 5/47 11/47 21/48 38/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 5/48 10/48 18/48 30/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 7/48 9/48 23/48 COMBINED 5/48 17/48 24/48 37/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 6/48 8/48 9/48 33/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 5/48 4/48 5/48 17/48 COMBINED 11/48 11/48 14/48 40/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 10/48 16/48 19/47 35/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 3/48 8/47 24/48 COMBINED 11/48 19/48 24/47 43/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) BENIGN GRANULOSA CELL TUMOR 0/46 0/47 5/46 3/45 BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/46 0/47 6/46 3/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47)
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48)
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/46 0/46 3/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/46 0/46 1/46 3/46
|
Neoplastic Lesions
|